Pentoxifylline+Tocopherol
Phase 2Small molecule
Pentoxifylline+Tocopherol is one of 17 small molecule programs targeting Osteonecrosis. It is currently in Phase 2.
2
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in Osteonecrosis
#DrugCompanyPhaseTrials
1Fosamax
OOrganon and Co
Approved
Bayer Aspirin
BayerPhase 3
Antibiotics
MMelinta Therapeutics, Inc.
Approved
Boniva
CConrado Roberto Hoffmann Filho
Phase 3
Trental
VValidus Pharmaceuticals
Phase 3
Zometa
PfizerPhase 2
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Tocopherol
MM.D. Anderson Cancer Center
Phase 3
Ixmyelocel-T
VVericel Corporation
Phase 3
Ibandronate IV
NNational Taiwan University Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pentoxifylline+Tocopherol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Limoges